Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1

Asako Takeuchi; Toshinori Kondo; Taizo Tasaka; Seiko Yamada; Tadashi Hirose; Hirofumi Fukuda; Risa Shimizu; Yoshiko Matsuhashi; Eisei Kondo; Hideho Wada

doi:10.1016/j.lrr.2020.100233

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1

Leuk Res Rep. 2020 Dec 14:15:100233. doi: 10.1016/j.lrr.2020.100233. eCollection 2021.

Authors

Affiliations

¹ Department of Hematology, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama Prefecture 701-0192, Japan.
² Department of Transfusion Medicine and Cell Therapy, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan.

Abstract

Acute myeloid leukemia (AML) with BCR-ABL1 is rare and has a poor prognosis with conventional chemotherapy or ABL tyrosine kinase inhibitors (TKIs) alone. We reported a case of AML with BCR-ABL1 patient who was successfully treated with dasatinib alone; additionally, we previously reported another case of long-term remission maintained with imatinib monotherapy. These results suggested that a treatment with a novel and significantly potent TKI may be effective in AML with BCR-ABL1 patients with low tumor burden and without additional chromosome aberrations and ABL kinase domain mutations.

Keywords: Acute myeloid leukemia; BCR-ABL1; Philadelphia chromosome; Tyrosine kinase inhibitor.

Publication types

Case Reports